Atea ( AVIR ) Q2 Loss Narrows 8%
Atea Pharmaceuticals ( NASDAQ:AVIR ) , a biopharmaceutical company focused on developing therapies for viral diseases, reported its second quarter 2025 results on August 7, 2025. The release highlighted improving cost controls and continued advancement in its Phase 3 clinical program for ...
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
BOSTON, July 31, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( Atea or Company ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live ...
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 - Atea Pharmaceuticals ( NASDAQ:AVIR )
BOSTON, July 31, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. AVIR ( Atea or Company ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call ...
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program. the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada ...
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America - Atea Pharmaceuticals ( NASDAQ:AVIR )
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with ...
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of ...
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - Atea Pharmaceuticals ( NASDAQ:AVIR )
Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Atea's First Quarter 2025 Earnings Conference Call.
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
BOSTON, April 23, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( Atea or Company ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the full results from ...
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - Atea Pharmaceuticals ( NASDAQ:AVIR )
BOSTON, April 23, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Enters into Agreement with Bradley L. Radoff and Michael Torok Enters into Agreement with Bradley L. Radoff and Michael Torok ...
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - Atea Pharmaceuticals ( NASDAQ:AVIR ) , Coya Therapeutics ( NASDAQ:COYA )
BOSTON, April 17, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. AVIR ( "Atea" or "Company" ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H.
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect ...
Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination
States Change in Board Composition Sorely Needed Expresses Support for Radoff-JEC Group Nominees
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - Atea Pharmaceuticals ( NASDAQ:AVIR )
BOSTON, March 26, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. AVIR ( Atea or Company ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement:
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
BOSTON, March 26, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( Atea or Company ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement: ...
Atea Pharmaceuticals Issues Statement Regarding Director Nominations - Atea Pharmaceuticals ( NASDAQ:AVIR )
BOSTON, March 21, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. AVIR ( Atea or Company ) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today confirmed receipt of a notice from Bradley L.
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
No Shareholder Action is Required at this Time No Shareholder Action is Required at this Time ...
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research ( ICAR ) 2025
BOSTON, March 19, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( Atea or Company ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the poster presentation of ...
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research ( ICAR ) 2025 - Atea Pharmaceuticals ( NASDAQ:AVIR )
BOSTON, March 19, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc.
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial - Atea Pharmaceuticals ( NASDAQ:AVIR )
Atea missed Q4 EPS estimates with a $0.40 loss, wider than the expected $0.37 loss. Phase 2 HCV study met primary endpoints, showing a 98% SVR12 rate. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential. Get the latest picks today before they gain traction.
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 - Atea Pharmaceuticals ( NASDAQ:AVIR )
BOSTON, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. AVIR ( "Atea" ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and ...
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
BOSTON, Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( Atea or Company ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S.
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Atea Pharmaceuticals ( NASDAQ:AVIR )
BOSTON, Jan. 08, 2025 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
BOSTON, Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( Atea or Company ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged ...
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study - Atea Pharmaceuticals ( NASDAQ:AVIR )
On Wednesday, Atea Pharmaceuticals, Inc. AVIR released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling and can lead to serious liver damage.
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus ( HCV )
Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment ( SVR12 ) after Short Eight Week Treatment Duration ...
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus ( HCV ) - Atea Pharmaceuticals ( NASDAQ:AVIR )
Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment ( SVR12 ) after Short Eight Week Treatment Duration Regimen Was Generally Safe and Well-Tolerated Global Phase 3 Program Initiation Expected Early in 2025
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
BOSTON, Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( "Atea" ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, ...
Is Atea Pharmaceuticals ( AVIR ) Stock Outpacing Its Medical Peers This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024
BOSTON, Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( "Atea" ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations ...
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. Stock rises in pre-market.
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
APLS' earnings and revenues miss third-quarter 2024 estimates. Syfovre drives revenues year over year.
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
Expanding transplant logistic service business is likely to have driven TransMedics' third-quarter 2024 performance.
HSIC Gears Up for Q3 Earnings: Here's What You Need to Know
Henry Schein is expected to report impressive sales in both its businesses in the third quarter of 2024, along with a low pace of recovery from the cyber incident.
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.
CRL Gears Up for Q3 Earnings: Here's What You Need to Know
Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.
Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards?
Within Spatial Biology, TECH is expected to have recorded strong growth, banking on the strong adoption of its new spatial biology instrument COMET.
STE Gears Up for Q2 Earnings: Here's What You Need to Know
STERIS' second-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog.
BIO Gears Up for Q3 Earnings: Here's What You Need to Know
Within Bio-Rad's Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely affected sales.
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock? - Atea Pharmaceuticals ( NASDAQ:AVIR ) , RadNet ( NASDAQ:RDNT )
Zimmer Biomet Holdings, Inc. ZBH is scheduled to report third-quarter 2024 results on Oct. 30, before market open. In the last reported quarter, the company's earnings of $2.01 beat the Zacks Consensus Estimate by 1.5%. ZBH beat on earnings in each of the trailing four quarters, the average ...
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
ABT delivers a strong underlying base business performance in the third quarter of 2024.
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
Are Medical Stocks Lagging Atea Pharmaceuticals ( AVIR ) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.
New Strong Buy Stocks for October 16th
CLPR, REE, HMY, AVIR and WPRT have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2024.
Atea Pharmaceuticals ( AVIR ) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Atea Pharmaceuticals (AVIR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is Atea Pharmaceuticals ( AVIR ) Stock Outpacing Its Medical Peers This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus - Atea Pharmaceuticals ( NASDAQ:AVIR )
On Friday, Atea Pharmaceuticals Inc. AVIR announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for COVID-19.
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Adobe ( NASDAQ:ADBE )
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday. Shares of Adobe Inc. ADBE shares declined 10.3% to $75.02 in pre-market trading after the company reported quarterly results. Adobe reported better-than-expected earnings for its third quarter on ...
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
BOSTON, Sept. 13, 2024 ( GLOBE NEWSWIRE ) -- Atea Pharmaceuticals, Inc. ( Nasdaq: AVIR ) ( "Atea" ) , a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the outcome of the global Phase 3 ...
